HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS

This study compared 6 vs 12 or more months of dual antiplatelet therapy (DAPT) in patients undergoing acute...
solaci -
Learn More
Antiplatelet

ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding

Ticagrelor seems as safe as clopidogrel in patients undergoing ST elevation MI treated with fibrinolytics, at least in terms...
solaci -
Learn More
Antiplatelet

Dual Antiplatelet Therapy: Less Is More for Elderly Patients

A recent meta-analysis that will be published soon in JACC Intv offers evidence of benefit derived from...
solaci -
Learn More
Antiplatelet

Transulnar Access: Another Ace Up Our Sleeve Before Transfemoral Access

Transulnar access can be as safe and effective as transradial access, and it is a particularly good...
solaci -
Learn More
Antiplatelet

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients, JACC publishes...
solaci -
Learn More
Antiplatelet

What Is the Best Antiplatelet Therapy in Primary Angioplasty at 12 Months?

Both prasugrel and ticagrelor showed superiority in terms of efficacy, reducing the number of major cardiovascular events...
solaci -
Learn More
Carotid

The new HTA guides 2017 could be up to their predecessors

From the first reports, back in 1920, we have studied, recognized and documented the excess of events...
solaci -
Learn More
Aorta

What is the effect of statins on amputations, and survival in peripheral vascular disease?

The prevalence of peripheral arterial disease is between 15% and 20% of patients older than 65 years...
solaci -
Learn More